Blood platelets play a fundamental role in hemostasis and thrombosis. The physiological role of platelets is to preserve the integrity of the cardiovascular system such that upon injury platelets are activated and serve to interrupt a potentially deleterious situation (i.e., hemorrhage). However, platelets are also involved in the pathophysiology of thrombosis in which the normal repair process is grossly exacerbated, resulting in interruption of blood flow to vital tissues. Thus, a critical balance exists between the normal function of blood platelets to preserve tissue function and a pathophysiological function in which tissue is damaged due to thrombosis and subsequent ischemia. Numerous anti-platelet agents have been developed in an attempt to interrupt the thrombotic process without severely compromising the hemostatic state of patients. This article will be devoted to a discussion of a commonly utilized anti-thrombotic agent, aspirin, as well as a class of newer, possibly more effective anti-thrombotic agents referred to collectively as fibrinogen receptor antagonists.
Aiken JW and Shebuski RJ (1980). Comparison in anesthetized dogs of the anti-aggregatory and hemodynamic effects of prostacyclin and a chemically stable prostacyclin analog, 6a-carba-PGI2 (carbacyclin). Prostaglandins19: 629-643.
2.
Altman R., Boullon F., Rouvier J., Raca R., de La Fuente L., and Favaloro R. (1976). Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves. J. Thorac. Cardiovasc. Surg. 72: 127-129.
3.
Bush LR and Shebuski RJ (1990). In vivo models of arterial thrombosis and thrombolysis . FASEB J. 4: 3087-3098.
4.
Cairns JA, Gent M., and Singer J. (1985). Aspirin, sulfinpyrazone, or both in unstable angina: Results of a Canadian multicentre trial. N. Engl. J. Med. 313: 1369-1374.
5.
The Canadian Cooperative Study Group (1978). A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N. Engl. J. Med. 299: 53-59.
6.
Catalono PM, Smith JB, and Murphy S. (1981). Platelet recovery from aspirin inhibition in vivo: Differing patterns under different assay conditions. Blood57: 99-105.
7.
Clarke RJ, Mayo G., Price P., and FitzGerald GA (1991). Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N. Engl. J. Med . 325: 1137-1141.
8.
Coller BS, Folts JD, Scudder LE, and Smith SR (1986). Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model . Blood68: 783-786.
9.
Coller BS and Scudder LE (1985). Inhibition of dog platelet function by in vivo infusion of F(ab1)2) fragments of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor. Blood66: 1456-1459.
10.
Cook JJ, Huang T.-F, Rucinski B., Strzyzewiski M., Tuma RF, Williams JA, and Niewiarowski S. (1989). Inhibition of platelet hemostatic plug formation by trigramin, a novel RGD-peptide. Am. J. Physiol. 256: H1038-H1043.
11.
Dale J., Myhre E., Storstein O., Stormorken H., and Efskind L. (1977). Prevention of arterial thromboembolism with acetylsalicylic acid. A controlled clinical study in patients with substitute heart valves . Am. Heart J. 94: 101-111.
12.
DeWood MA, Spores J., Notske R., Mouser LT, Bur-roughs R., Golden MS, and Lang HT (1980). Prevalence of coronary occlusion during the early hours of transmural myocardial infarction. N. Engl. J. Med. 303: 897-902.
13.
Fields WS, Lemak NA, Frankowski RF, and Hardy RJ (1977). Controlled trial of aspirin in cerebral ischemia . Stroke8: 301-314.
14.
Fitzgerald DJ, Catella F., Roy L., and FitzGerald GA (1988). Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation77: 142-150.
15.
Fitzgerald DJ, Roy L., Catella F., and FitzGerald GA (1986). Platelet activation in unstable angina. N. Engl. J. Med. 315: 983-989.
16.
FitzGerald GA, Oates JA, and Hawiger J. (1983). Endogenous synthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J. Clin. Invest. 71: 676-688.
17.
Folts JD, Crowel ED, and Rowe GG (1976). Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation54: 365-370.
18.
Gan Z.-R, Gould RJ, Jacobs JW, Friedman PA, and Polokoff MA (1988). Echistatin: A potent platelet aggregation inhibitor from the venom of the viper, Echis carinatus. J. Biol. Chem . 263: 19827-19832.
19.
Gartner TK and Bennett JS (1985). The tetrapeptide analogue of the cell attachment site of fibrinectin inhibits platelet aggregation and fibrinogen binding to activate platelets. J. Biol. Chem. 260: 11891-11894.
20.
Gold HK, Coller BS, Yasuda T., Saito T., Fallon JT, Guerrero JL, Leinbach RC, Zisking AA, and Collen D. (1988). Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation77: 670-677.
21.
Gold HK, Gimple T., Yasuda RS, Leinbach RC, Jordan J. and Coller BS (1989). Phase I human trial of the potent antiplatelet agent, 7E3-F(ab')2, a monoclonal antibody to the GPIIb/IIIa receptor. Circulation80(II): 267 (abstract).
22.
Gold HK, Gimple LW, Yasuda T., Leinbach RC, Werner W., Holt R., Jordan R., Berger H., Collen D., and Coller BS (1990). Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J. Clin. Invest. 86: 651-659.
23.
Harter HR, Burch JW, Majerus PW, Stanford N., and Delmez JA (1979). Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. N. Engl. J. Med. 301: 577-579.
24.
Haskel EJ, Adams SP, Feigen LP, Saffitz JE, Gorczynski RJ, Sobel BE, and Abendschein DR (1989). Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein IIb/IIIa receptors. Circulation80: 1775-1782.
25.
Holahan MA, Mellot MJ, Garsky VM, and Shebuski RJ (1991). Prevention of reocclusion following tissue type plasminogen activator-induced thrombolysis by the RGD-containing peptide, echistatin, in a canine model of coronary thrombosis. Pharmacology42: 340-348.
26.
Huang T.-F, Holt JC, Lukasiewicz H., and Niewiarowski S. (1987). Trigramin: A low molecular weight peptide inhibiting fibrinogen interaction with platelet receptors expressed in glycoprotein IIb/IIIa complex. J. Biol. Chem. 262: 16157-16163.
27.
ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988). Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet2: 349-360.
28.
Kloczewiak M., Timmons S., Lukas TJ, and Hawiger J. (1984). Platelet receptor recognition site on human fibrinogen: Synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the a chain. Biochemistry23 : 1767-1774.
29.
Lewis HD, David JW, and Archibald DG (1983). Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N. Engl. J. Med. 309: 396-403.
30.
Nichols A., Vasko J., Koster P., Smith J., Barone F., Nelson A., Stadel D., Powers G., Rhodes C., Miller-Stein B., Boppana D., Bennett D., Berry D., Romoff T., Calvo R., Ali F., Sorenson E., and Samanen J. (1990). SK and F 106760, a novel GPIIB/IIIA antagonist: Antithrombotic activity and potentiation of streptokinase-mediated thrombolysis . Eur. J. Pharmacol. 183: 2019 (abstract).
31.
Nicholson NS , Panzer-Knodle SG, Salyers AK, Taite BB, King LW, Miyano M., Gorczynski RJ, Williams MH, Zupec ME, Tjoeng FS, Adams SP, and Feigen LP (1991). In vitro and in vivo effects of a peptide mimetic (SC-47643) of RGD as an antiplatelet and antithrombotic agent. Thromb. Res. 62: 567-578.
32.
Ohlstein EH , Storer B., Fujita T., and Shebuski RJ (1987) Tissue-type plasminogen activator and streptokinase induce platelet hyperaggregability in the rabbit . Thromb. Res. 46: 575-585.
33.
Patrignani P., Filabozzi P., and Patrono C. (1982). Selective, cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J. Clin. Invest. 69: 1366-1372.
34.
Patrono C., Ciabattoni G., and Patrignani P. (1985). Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation72: 1177-1184.
35.
Pedersen AK and FitzGerald GA (1984). Dose-related kinetics of aspirin: Presystemic acetylation of platelet cyclooxygenase. N . Engl. J. Med. 311: 1211-1214.
36.
Plow EF, Marguerie G., and Ginsberg M. (1987). Fibrinogen, fibrinogen receptors, and the peptides that inhibit these interactions. Biochem. Pharmacol. 36: 4035-4040.
37.
Reilly IAG and FitzGerald GA (1987). Inhibition of thromboxane formation in vivo and ex vivo: Implications for therapy with platelet inhibitory drugs. Blood69: 180-186.
38.
Shebuski RJ , Berry DE, Bennett DB, Romoff T., Storer BL, Ali F., and Samanen J. (1989). Demonstration of Ac-Arg-Gly-Asp-Ser-NH2 as an antiaggregatory agent in the dog by intracoronary administration. Thromb. Haemost. 61: 183-188.
39.
Shebuski RJ , Bloom JC, Sellers TS, Fujita T., Storer B., Horohonich S., Fong KL, and Ohlstein EH (1989). Attenuation of the inhibitory effect of prostacyclin on platelet function after tissue plasminogen activator or streptokinase infusion in the rabbit . Fibrinolysis3: 115-123.
40.
Shebuski RJ , Ramjit DR, Bencen GH, and Polokoff MA (1989). Characterization and platelet inhibitory activity of bitistatin, a potent arginine-glycine-aspartic acid-containing peptide from the venom of the viper Bitis arietans. J. Biol. Chem. 264: 21550-21556.
41.
Shebuski RJ , Ramjit DR, Sitko GR, Lumma PK, and Garsky VM (1990). Prevention of canine coronary artery thrombosis with echistatin, a potent inhibitor of platelet aggregation from the venom of the viper, Echis carinatus . Thromb. Haemost. 64: 576-581.
42.
Shebuski RJ , Stabilito IJ, Sitko GR, and Polokoff MA (1990). Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis. Circulation82:169-177.
43.
Steering Committee of the Physicians Health Study Research Group (1989). Final Report on the Aspirin Component of the Ongoing Physicians' Health Study. N. Engl. J. Med. 321: 129-135.
44.
Weksler BB, Pett SB, and Alonso D. (1983). Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N. Engl. J. Med. 308: 800-805.
45.
Weksler BB, Tack-Goldman K., Subramanian VA, and Gay WA (1985). Cumulative inhibitory effect of low dose asnirin on vascular prostacvclin and platelet thromboxane production in patients with atherosclerosis. Circulation71: 332-340.
46.
Yasuda T., Gold AK, Fallon JT, Leinbach RC, Guerrero JL, Scudder LE, Kanke M., Shealy D., Roos MJ, Collen D., and Coller BS (1988). Monoclonal antibody against the platelet glycoprotein GPIIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. J. Clin. Invest. 81: 1284-1291.
